Journal of the National Comprehensive Cancer Network : JNCCN

NCCN Guidelines® Insights: Hematopoietic Cell Transplantation, Version 3.2022.  21:108-115. 2023

Uterine Neoplasms, Version 1.2023, NCCN Clinical Practice Guidelines in Oncology.  21:181-209. 2023

NCCN GUIDELINES^® INSIGHTS: Central Nervous System Cancers, Version 2.2022.  21:12-20. 2023

Systemic Light Chain Amyloidosis, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology.  21:67-81. 2023

NCCN GUIDELINES® INSIGHTS: Prostate Cancer, Version 1.2023: Featured Updates to the NCCN Guidelines.  20:1288-1298. 2022

Healthcare Access Dimensions and Guideline-Concordant Ovarian Cancer Treatment: SEER-Medicare Analysis of the ORCHiD Study.  20:1255-1266E11. 2022

Survivorship, Version 1.2022 Featured Updates to the NCCN Guidelines.  20:1080-1090. 2022

Myeloproliferative Neoplasms, Version 3.2022.  20:1033-1062. 2022

Ovarian Cancer, Version 3.2022 Featured Updates to the NCCN Guidelines.  20:973-980. 2022

Bladder Cancer, Version 2.2022 Featured Updates to the NCCN Guidelines.  20:866-878. 2022

Breast Cancer, Version 3.2022.  20:691-722. 2022

Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma, Version 3.2022 Featured Updates to the NCCN Guidelines.  20:622-634. 2022

Near Complete Response to Trametinib Treatment in Histiocytic Sarcoma Harboring a Somatic KRAS Mutation.  20:618-621. 2022

Hematopoietic Growth Factors, Version 1.2022 Featured Updates to the NCCN Guidelines.  20:436-442. 2022

Non-Small Cell Lung Cancer, Version 3.2022.  20:497-530. 2022

Management of Immunotherapy-Related Toxicities, Version 1.2022.  20:387-405. 2022

Nonoperative Treatment of Large (5–7 cm), Node-Negative Non–Small Cell Lung Cancer Commonly Deviates From NCCN Guidelines.  20:371-377. 2022

Head and Neck Cancers, Version 1.2022 Featured Updates to the NCCN Guidelines.  20:225-234. 2022

Myelodysplastic Syndromes, Version 3.2022: Featured Updates to the NCCN Guidelines.  20:106-117. 2022

Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.  20:71-90. 2022

Multiple Myeloma, Version 3.2022: Featured Updates to the NCCN Guidelines.  20:8-19. 2022

Representation and Outcomes of Older Adults in Practice-Changing Oncology Trials in the Era of Novel Therapies: A Guideline Appraisal.  20:37-44. 2022

B-cell lymphomas, version 5.2021. Featured updates to the NCCN guidelines.  19:1218-1230. 2021

Histiocytic neoplasms, version 2.2021.  19:1277-1303. 2021

Cancer-associated venous thromboembolic disease, version 2.2021.  19:1181-1201. 2021

Older adult oncology, version 1.2021: Featured updates to the NCCN guidelines.  19:1006-1019. 2021

Association between chronologic age and geriatric assessment⇓identified impairments: Findings from the CARE registry.  19:922-927. 2021

Uterine neoplasms, version 3.2021 featured updates to the NCCN guidelines.  19:889-895. 2021

Neuroendocrine and adrenal tumors, version 2.2021.  19:839-867. 2021

Association Between Chronologic Age and Geriatric Assessment-Identified Impairments: Findings From the CARE Registry..  19:922-927. 2021

Survivorship, version 1.2021 featured updates to the NCCN guidelines.  19:676-685. 2021

Barriers to optimal end-of-life care for adolescents and young adults with cancer: Bereaved caregiver perspectives.  19:528-533. 2021

Breast cancer, version 4.2021 featured updates to the NCCN guidelines.  19:484-494. 2021

Hepatobiliary cancers, Version 2.2021.  19:541-565. 2021

QIM21-084: Perceived Needs and Patient Satisfaction of Psychosocial Distress Screening and Management in Inpatient Hematology Oncology Specialty Care.  19:qim21-qi084. 2021

Considerations for Use of Hematopoietic Growth Factors in Patients With Cancer Related to the COVID-19 Pandemic.  19:18-21. 2021

Non-small cell lung cancer, Version 2.2021 featured updates to the NCCN guidelines.  19:254-266. 2021

Ovarian cancer, version 2.2020.  19:191-226. 2021

Prostate cancer, version 1.2021: Featured updates to the nccn guidelines.  19:134-143. 2021

Acute Myeloid Leukemia, Version 2.2021 Featured Updates to the NCCN Guidelines.  19:16-27. 2021

Genetic/familial high-risk assessment: Breast, ovarian, and pancreatic, version 2.2021.  19:77-102. 2021

Defining and managing high-risk multiple myeloma: Current concepts.  18:1730-1737. 2020

Multiple myeloma, version 3.2021.  18:1685-1717. 2020

Soft Tissue Sarcoma, Version 1.2021: Featured updates to the NCCN guidelines.  18:1605-1612. 2020

Central nervous system cancers, version 3.2020.  18:1537-1570. 2020

T-cell lymphomas, version 1.2021 featured updates to the NCCN guidelines.  18:1460-1467. 2020

Chronic myeloid leukemia, version 2.2021.  18:1385-1415. 2020

Colorectal cancer screening, version 2.2020 featured updates to the NCCN guidelines.  18:1312-1320. 2020

Kidney cancer, version 1.2021: Featured updates to the nccn guidelines.  18:1160-1170. 2020

Myeloid/lymphoid neoplasms with eosinophilia and TK fusion genes, version 3.2021.  18:1248-1269. 2020

Survivorship, version 2.2020: Featured updates to the NCCN guidelines.  18:1016-1023. 2020

Head and neck cancers, version 2.2020.  18:873-898. 2020

Cervical cancer, Version 1.2020 featured updates to the NCCN guidelines.  18:660-666. 2020

Hematopoietic cell transplantation, Version 2.2020.  18:599-634. 2020

Primary cutaneous lymphomas, version 2.2020. Featured updates to the NCCN guidelines.  18:522-536. 2020

Breast cancer, version 3.2020.  18:452-478. 2020

Genetic/familial high-risk assessment: Breast, ovarian, and pancreatic, version 1.2020 featured updates to the NCCN guidelines.  18:380-391. 2020

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 4.2020, NCCN Clinical Practice Guidelines in Oncology.  18:185-217. 2020

Bladder cancer, version 3.2020.  18:329-354. 2020

Hematopoietic growth factors, version 1.2020: Featured updates to the NCCN guidelines.  18:12-22. 2020

Management of immunotherapy-related toxicities, version 1.2020 featured updates to the NCCN guidelines.  18:231-241. 2020

Management of Central Nervous System Tumors.  17:579-582. 2019

Hepatobiliary cancers, version 2.2019 featured updates to the NCCN guidelines.  17:302-310. 2019

Impact of hydroxyurea on survival and risk of thrombosis among older patients with essential thrombocythemia.  17:211-219. 2019

Management of immunotherapy-related toxicities, version 1.2019.  17:255-289. 2019

AIDS-related Kaposi sarcoma, version 2.2019.  17:171-189. 2019

Adult cancer pain, version 3.2019.  17:977-1007. 2019

B-cell lymphomas, version 3.2019: Featured updates to the NCCN Guidelines.  17:650-661. 2019

Cervical cancer, version 3.2019.  17:64-84. 2019

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2019.  17:12-20. 2019

Distress management, version 3.2019.  17:1229-1249. 2019

Featured updates to the NCCN guidelines.  17:1278-1285. 2019

Genetic/Familial high-risk assessment: Colorectal, version 2.2019 featured updates to the NCCN guidelines.  17:1032-1041. 2019

Gestational trophoblastic neoplasia, version 2.2019.  17:1374-1391. 2019

Guideline discordance and patient cost responsibility in medicarebeneficiaries with metastatic breast cancer.  17:1221-1228. 2019

Lung cancer in nonelderly patients: Facility and patient characteristics associated with not receiving treatment.  17:931-939. 2019

Multiple myeloma, version 1.2020 featured updates to the NCCN guidelines.  17:1154-1165. 2019

Non-small cell lung cancer, version 1.2020: Featured updates to the NCCN guidelines.  17:1464-1472. 2019

Ovarian cancer, version 1.2019 featured updates to the nccn guidelines.  17:896-909. 2019

Physician experience and risk of rituximab discontinuation in older adults with non-hodgkin's lymphoma.  17:1194-1202. 2019

Prostate cancer, version 2.2019.  17:479-505. 2019

Survivorship, version 2.2019 featured updates to the NCCN guidelines.  17:785-794. 2019

Testicular cancer, version 2.2020.  17:1529-1554. 2019

Electronic clinical decision tools for improving adherence to colon cancer surveillance guidelines: Can the chips finally fall into place?.  16:1406-1408. 2018

NCCN Guidelines^® insights cancer-associated venous thromboembolic disease, version 2.2018 featured updates to the NCCN guidelines.  16:1289-1303. 2018

First-line treatment of widely metastatic BRAF-mutated salivary duct carcinoma with combined BRAF and MEK inhibition.  16:1166-1170. 2018

NCCN guidelines® insights: Small cell lung cancer, version 2.2018 featured updates to the NCCN guidelines.  16:1171-1182. 2018

Survivorship, version 2.2018: Clinical practice guidelines in oncology.  16:1216-1247. 2018

Chronic myeloid leukemia, version 1.2019.  16:1108-1135. 2018

Impact of nonconcordance with NCCN guidelines on resource utilization, cost, and mortality in de novo metastatic breast cancer.  16:1084-1091. 2018

Cancer in people living with HIV, version 1.2018: Clinical practice guidelines in oncology.  16:986-1017. 2018

Letter to the editor: Integrating skeletal muscle mass and radiodensity improves outcome prediction and correlation in oncologic studies.  16:923-924. 2018

NCCN Guidelines(r) insights colorectal cancer screening, version 1.2018 featured updates to the NCCN guidelines.  16:939-949. 2018

NCCN guidelines ^® insights non–small cell lung cancer, version 5.2018 featured updates to the NCCN guidelines.  16:807-821. 2018

Neuroendocrine and adrenal tumors, version 2.2018 featured updates to the nccn guidelines.  16:693-702. 2018

Receipt of guideline-concordant care among older women with stage i-III breast cancer: A population-based study.  16:703-710. 2018

Head and neck cancers: Advantages of advanced radiation therapy and importance of supportive care.  16:666-669. 2018

NCCN guidelines ^® insights: Head and neck cancers, version 1.2018 featured updates to the NCCN guidelines.  16:479-490. 2018

Soft tissue sarcoma, version 2.2018: Clinical practice guidelines in oncology.  16:536-563. 2018

Lung cancer screening, version 3.2018.  16:412-441. 2018

T-Cell Lymphomas, Version 2.2018 Featured Updates to the NCCN Guidelines.  16:123-135. 2018

Uterine Neoplasms, Version 1.2018: Clinical practice guidelines in oncology.  16:170-199. 2018

Adolescent and young adult oncology, version 2.2018: Clinical practice guidelines in oncology.  16:66-97. 2018

Multiple Myeloma, version 3.2018: Featured updates to the NCCN guidelines.  16:11-20. 2018

NCCN guidelines^® insights: Genetic/Familial High-Risk Assessment: Colorectal, version 3.2017 featured updates to the NCCN Guidelines.  15:1465-1475. 2017

Central nervous system cancers, version 1.2017 featured updates to the NCCN guidelines.  15:1331-1345. 2017

Hairy cell Leukemia, Version 2.2018: Clinical practice guidelines in oncology.  15:1414-1427. 2017

Myeloproliferative neoplasms, version 2.2018 featured Updates to the NCCN guidelines.  15:1193-1207. 2017

Survivorship, Version 2.2017: Clinical practice guidelines in oncology.  15:1140-1163. 2017

Antiemesis, version 2.2017 featured updates to the NCCN guidelines.  15:883-893. 2017

Frailty index developed from a cancer-specific geriatric assessment and the association with mortality among older adults with cancer.  15:894-902. 2017

NCCN guidelines^® insights head and neck cancers, version 2.2017 featured updates to the NCCN guidelines.  15:761-770. 2017

Thrombotic Thrombocytopenic Purpura Associated With Pegylated Interferon Alfa-2a Use in a Patient With Polycythemia Vera.  15:757-760. 2017

Hepatobiliary cancers, version 1.2017 featured updates to the NCCN guidelines.  15:563-573. 2017

NCCN Guidelines Insights: Hepatobiliary Cancers, Version 1.2017..  15:563-573. 2017

Non-small cell lung cancer, version 5.2017: Clinical practice guidelines in oncology.  15:504-535. 2017

NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 1.2017..  15:293-311. 2017

NCCN guidelines® insights chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia, Version 1.2017: Featured updates to the NCCN guidelines.  15:293-311. 2017

Predictors of nonadherence to NCCN guideline recommendations for the management of stage i anal canal cancer.  15:355-362. 2017

Bone cancer, version 2.2017 featured updates to the NCCN guidelines.  15:155-167. 2017

Clinical practice guidelines in oncology.  15:230-269. 2017

NCCN Guidelines Insights: Bone Cancer, Version 2.2017..  15:155-167. 2017

Vulvar cancer, version 1.2017: Clinical practice guidelines in oncology.  15:92-120. 2017

Myeloproliferative neoplasms, version 2.2017: Clinical Practice Guidelines in oncology.  14:1572-1611. 2016

NCCN Guidelines Insights: Chronic Myeloid Leukemia, Version 1.2017..  14:1505-1512. 2016

NCCN guidelines^® insights: Chronic myeloid leukemia, version 1.2017: Featured updates to the NCCN guidelines.  14:1505-1512. 2016

Smoking cessation, version 1.2016 clinical practice guidelines in oncology.  14:1430-1468. 2016

Genetic/familial high-risk assessment: Colorectal version 1.2016: Clinical practice guidelines in oncology.  14:1010-1030. 2016

NCCN Guidelines Insights: Melanoma, Version 3.2016..  14:945-958. 2016

NCCN Guidelines^® insights: Melanoma, version 3.2016: Featured updates to the NCCN Guidelines.  14:945-958. 2016

NCCN Guidelines®: Insights malignant pleural mesothelioma, version 3.2016.  14:825-836. 2016

Value, access, and cost of cancer care delivery at academic cancer centers.  14:837-847. 2016

NCCN Guidelines Insights: Survivorship, Version 1.2016..  14:715-724. 2016

NCCN guidelines^® insights survivorship, version 1.2016 featured updates to the NCCN Guidelines.  14:715-724. 2016

Soft tissue sarcoma, version 2.2016: Clinical practice guidelines in oncology.  14:758-786. 2016

Basal cell skin cancer, version 1.2016: Clinical practice guidelines in oncology.  14:574-597. 2016

Central nervous system: Notable developments in the management of primary and recurrent gliomas.  14:681-684. 2016

NCCN Guidelines Insights: Prostate Cancer Early Detection, Version 2.2016..  14:509-519. 2016

Prostate cancer early detection, Version 2.2016: Featured updates to the NCCN guidelines.  14:509-519. 2016

Guiding lay navigation in geriatric patients with cancer using a distress assessment tool.  14:407-414. 2016

Melanoma, version 2.2016 clinical practice guidelines in oncology.  14:450-473. 2016

NCCN Guidelines Insights: Multiple Myeloma, Version 3.2016..  14:389-400. 2016

NCCN guidelines^® insights multiple myeloma, version 3.2016 featured updates to the NCCN guidelines.  14:389-400. 2016

NCCN guidelines® Insights: Non-small cell lung cancer, version 4.2016 Featured updates to the NCCN guidelines.  14:255-264. 2016

NCCN Clinical Practice Guidelines Prostate Cancer Early Detection, Version 2.2015..  13:1534-1561. 2015

Prostate cancer early detection, version 2.2015: Clinical practice guidelines in oncology.  13:1534-1561. 2015

Multiple myeloma, version 2.2016: Clinical practice guidelines in oncology.  13:1398-1435. 2015

Uterine sarcoma, version 1.2016: Featured updates to the NCCN Guidelines.  13:1321-1331. 2015

Central Nervous System Cancers, Version 1.2015..  13:1191-1202. 2015

Central nervous system cancers, version 1.2015: Featured updates to the NCCN guidelines.  13:1191-1202. 2015

Next-generation sequencing and in silico analysis facilitate prolonged response to pazopanib in a patient with metastatic urothelial carcinoma of the renal pelvis.  13:1181-1185. 2015

Cancer-associated venous thromboembolic disease, version 1.2015: Featured updates to the NCCN Guidelines.  13:1079-1095. 2015

Colorectal cancer screening, version 1.2015: Featured updates to the NCCN guidelines.  13:959-968. 2015

Breast cancer risk reduction, version 2.2015 clinical practice guidelines in oncology clinical practice guidelines in oncology.  13:880-915. 2015

Head and neck cancers, version 1.2015 featured updates to the NCCN guidelines.  13:847-856. 2015

Non-Small Cell Lung Cancer, Version 6.2015..  13:515-524. 2015

Non-Small cell lung cancer, version 6.2015: Featured updates to the NCCN guidelines.  13:515-524. 2015

Sorafenib in relapsed AML with FMS-like receptor tyrosine kinase-3 internal tandem duplication mutation.  13:508-514. 2015

Cervical Cancer, Version 2.2015..  13:395-404. 2015

Cervical cancer, version 2.2015: Featured updates to the NCCN guidelines featured updates to the NCCN guidelines.  13:395-404. 2015

Historical views, conventional approaches, and evolving management strategies for myeloproliferative neoplasms.  13:424-434. 2015

Lung cancer screening, version 1.2015: Featured updates to the NCCN guidelines.  13:23-34. 2015

Neuroendocrine tumors, version 1.2015.  13:78-108. 2015

Central nervous system cancers, Version 2.2014: Featured updates to the NCCN guidelines.  12:1517-1523. 2014

Chronic myelogenous leukemia, version 1.2015.  12:1590-1610. 2014

Role of MRI in primary brain tumor evaluation.  12:1561-1568. 2014

Survivorship: Screening for cancer and treatment effects, version 2.2014.  12:1526-1531. 2014

Head and neck cancers, version 2.2014.  12:1454-1487. 2014

Survivorship: Nutrition and weight management, version 2.2014.  12:1396-1406. 2014

Survivorship: Healthy lifestyles, version 2.2014.  12:1222-1237. 2014

The role of bevacizumab in glioblastoma.  12:1201-1202. 2014

Survivorship: Immunizations and Prevention of Infections, Version 2.2014.  12:1098-1111. 2014

Occult primary, version 3.2014; Featured updates to the NCCN guidelines.  12:969-974. 2014

Survivorship: Cognitive function, Version 1.2014; Clinical practice guidelines in oncology.  12:976-986. 2014

Survivorship: cognitive function, version 1.2014..  12:976-986. 2014

Dermatofibrosarcoma protuberans, version 1.2014.  12:863-868. 2014

Gastrointestinal stromal tumors, version 2.2014..  12:853-862. 2014

Gastrointestinal stromal tumors, version 2.2014: Featured updates to the NCCN Guidelines.  12:853-862. 2014

Survivorship: Fatigue, version 1.2014 - Clinical practice guidelines in oncology.  12:876-887. 2014

Survivorship: fatigue, version 1.2014..  12:876-887. 2014

Melanoma, version 4.2014..  12:621-629. 2014

Soft tissue sarcoma, version 2.2014..  12:473-483. 2014

Survivorship: pain version 1.2014..  12:488-500. 2014

Uterine neoplasms, version 1.2014.  12:248-280. 2014

Adolescent and young adult oncology, version 2.2014..  12:21-32. 2014

Adolescent and young adult oncology, version 2.2014: Featured updates to the NCCN guidelines.  12:21-32. 2014

Melanoma, version 4.2014: Featured updates to the NCCN guidelines.  12:621-629. 2014

Merkel cell carcinoma, version 1.2014..  12:410-424. 2014

Soft tissue sarcoma, version 2.2014: Featured updates to the NCCN guidelines.  12:473-483. 2014

Survivorship: Pain version 1.2014 - Clinical practice guidelines in oncology.  12:488-500. 2014

Survivorship: Sleep disorders, version 1.2014.  12:630-642. 2014

Colorectal cancer screening: Clinical practice guidelines in oncology.  11:1538-1575. 2013

Chronic Myelogenous Leukemia, Version 1.2014..  11:1327-1340. 2013

Chronic myelogenous leukemia, version 1.2014: Featured updates to the NCCN guidelines.  11:1327-1340. 2013

Central nervous system cancers.  11:1114-1151. 2013

Head and Neck Cancers, version 2.2013.  11:917-923. 2013

An unusual presentation of chronic myelogenous leukemia: A review of isolated central nervous system relapse.  11:745-750. 2013

Bone Cancer: Clinical practice guidelines in oncology.  11:688-723. 2013

Bone cancer..  11:688-723. 2013

Cervical cancer: Clinical practice guidelines in oncology.  11:320-343. 2013

Melanoma, version 2.2013: Featured updates to the NCCN guidelines.  11:395-407. 2013

Multiple myeloma, version 1.2013: Featured updates to the NCCN guidelines.  11:11-17. 2013

Small cell lung cancer: Clinical practice guidelines in oncology.  11:78-98. 2013

Prevention and treatment of cancer-related infections.  10:1412-1445. 2012

Non-small cell lung cancer: Clinical practice guidelines in oncology.  10:1236-1271. 2012

Palliative care..  10:1284-1309. 2012

Palliative care: Clinical practice guidelines in oncology.  10:1284-1309. 2012

Waldenström's macroglobulinemia/lymphoplasmacytic lymphoma, version 2.2013: Featured updates to the NCCN guidelines.  10:1211-1219. 2012

Adolescent and young adult oncology clinical practice guidelines in oncology.  10:1112-1150. 2012

Soft tissue sarcoma, version 2.2012 featured updates to the NCCN guidelines.  10:951-960. 2012

Neuroendocrine tumors..  10:724-764. 2012

Neuroendocrine tumors: Clinical practice guidelines in oncology.  10:724-764. 2012

Dermatofibrosarcoma protuberans.  10:312-318. 2012

Melanoma.  10:366-400. 2012

Mucosal melanoma of the head and neck.  10:320-338. 2012

Mucosal melanoma: A clinically and biologically unique disease entity.  10:345-356. 2012

Senior adult oncology: Clinical practice guidelines in oncology.  10:162-209. 2012

Treatment of non-small cell lung cancer in the older patient.  10:230-239. 2012

By the pricking of my thumbs, something wicked this way comes*: Sporadic cancers versus eponymous hereditary cancer predisposition syndromes.  10:7-13. 2012

Chronic myelogenous leukemia.  10:64-110. 2012

Malignant pleural mesothelioma.  10:26-41. 2012

Multiple myeloma clinical practice guidelines in oncology.  9:1146-1183. 2011

Small cell lung cancer clinical practice guidelines in oncology.  9:1086-1113. 2011

Head and neck cancers: Clinical practice guidelines in oncology.  9:596-650. 2011

Central nervous system cancers: Clinical practice guidelines in oncology.  9:352-400. 2011

Cervical cancer: Clinical practice guidelines in oncology.  8:1388-1416. 2010

The changing face of cervical cancer screening in the United States.  8:1329-1330. 2010

Thymic malignancies.  8:1302-1315. 2010

Breast cancer risk reduction.  8:1112-1146. 2010

Distress management..  8:448-485. 2010

Basal cell and squamous cell skin cancers.  8:836-864. 2010

Bone cancer.  8:688-712. 2010

Distress management: Clinical practice guidelines in oncology™.  8:448-485. 2010

Non-small cell lung cancer: Clinical practice guidelines in oncology.  8. 2010

Soft tissue sarcoma.  8:630-674. 2010

NCCN Clinical Practice Guidelines in Oncology: neuroendocrine tumors..  7:712-747. 2009

NCCN clinical practice guidelines in oncology: palliative care..  7:436-473. 2009

Breast cancer screening and diagnosis: Clinical practice guidelines in oncology™.  7:1060-1096. 2009

Breast cancer: Clinical Practice Guidelines in Oncology™.  7:122-192. 2009

Chronic myelogenous leukemia.  7:984-1023. 2009

Melanoma.  7:250-275. 2009

Merkel cell carcinoma.  7:322-332. 2009

Multiple myeloma.  7:908-942. 2009

Myeloid growth factors.  7:64-83. 2009

NCCN Task Force Report: Management of dermatologic and other toxicities associated with EGFR inhibition in patients with cancer.  7:5-21. 2009

NCCN Task Force report: Molecular markers in leukemias and lymphomas.  7. 2009

Neuroendocrine tumors.  7:712-747. 2009

Palliative care.  7. 2009

Uterine neoplasms.  7:498-531. 2009

NCCN Task Force report: Breast cancer in the older woman.  6. 2008

Central nervous system cancers..  6:456-504. 2008

Acute myeloid leukemia.  6:962-992. 2008

Central nervous system cancers: Clinical Practice Guidelines in Oncology™.  6:456-504. 2008

Cervical cancer.  6:14-36. 2008

Cytology versus high-risk HPV testing for follow-up of HPV-positive women without CIN.  6:96-100. 2008

Head and neck cancers.  6:646-695. 2008

Myelodysplastic syndromes.  6:902-925. 2008

Non-small cell lung cancer.  6:228-269. 2008

Small cell lung cancer.  6:294-314. 2008

Bone cancer..  5:420-437. 2007

Soft tissue sarcoma..  5:364-399. 2007

Basal cell and squamous cell skin cancers.  5:506-529. 2007

Chronic myelogenous leukemia.  5:474-496. 2007

Dermatofibrosarcoma protuberans.  5:550-555. 2007

Distress management..  5:66-98. 2007

Myeloid growth factors: Clinical practice guidelines in oncology™.  5:188-202. 2007

The NCCN. Invasive breast cancer: Clinical practice guidelines in oncology™.  5:246-312. 2007

Thyroid carcinoma.  5:568-621. 2007

Melanoma..  4:666-684. 2006

Neuroendocrine tumors..  4:102-138. 2006

Acute myeloid leukemia: Clinical Practice Guidelines in Oncology.  4:16-36. 2006

Breast cancer screening and diagnosis: Clinical practice guidelines in oncology™.  4:480-508. 2006

Genetic/familial high-risk assessment: Breast and ovarian. Clinical Practice Guidelines in Oncology™.  4:156-176. 2006

Melanoma: Clinical practice guidelines in oncology™.  4:666-684. 2006

Myelodysplastic syndromes: Clinical Practice Guidelines in Oncology.  4:58-77. 2006

Neuroendocrine tumors: Clinical Practice Guidelines in Oncology™.  4:102-138. 2006

Non-small cell lung cancer: Clinical Practice Guidelines in Oncology™.  4:548-582. 2006

Palliative care clinical practice guidelines in oncology.  4:776-818. 2006

Small cell lung cancer: Clinical Practice Guidelines in Oncology™.  4:602-622. 2006

Bone cancer: Clinical practice guidelines.  3:124-140. 2005

Soft tissue sarcoma: Clinical practice guidelines in oncology.  3:158-194. 2005

Breast cancer: Clinical practice guidelines in oncology.  3:238-289. 2005

Chronic myelogenous leukemia: Clinical practice guidelines in oncology.  3:732-755. 2005

Head and neck cancers: Clinical practice guidelines.  3:316-391. 2005

Treatment options for merkel cell carcinoma.  2:89-92. 2004